JBM HEALTHCARE (02161) announces annual performance Equity holders' share of profit approximately HK$201 million, an increase of about 1.9% year-on-year.

JBM HEALTHCARE (02161) announced its financial results for the year ending March 31, 2026, with revenue of approximately HK$835 million, an increase of about 6.7% compared to the previous year. The profit attributable to equity holders of the company was approximately HK$201 million, an increase of about 1.9%. Earnings per share were 24.63 HK cents, with a final dividend of 7.35 HK cents per share. The announcement stated that the growth in revenue was mainly driven by strong performance in the branded drugs and branded traditional Chinese medicine divisions, partially offset by weaker performance in health and wellness products. Supported by stable market demand and effective marketing measures, revenue in the branded drugs division increased by HK$7.8 million, reflecting steady sales growth and heightened promotional efforts, while revenue in the branded traditional Chinese medicine division increased by HK$62.9 million. These gains were partially offset by a decrease in revenue of HK$18.4 million in the health and wellness products division, mainly due to product portfolio streamlining and softening consumer demand. The three divisions accounted for 34%, 56%, and 10% of total revenue, respectively.